Intarcia Therapeutics, Inc.

Durect Corporation

Catherine Manya Rohloff

Thomas R Alessi

Bing Yang

Ryan D Mercer

Pauline C Zamora

Stan Lam

Guohua Chen

Andrew S Luk

Rupal A Ayer

Paul R Houston

Michael A DesJardin

Gunjan H Junnarkar

Yuanpeng Zhang

Rom Ezer Eliaz

Eric William Weeks

Karling Alice Leung

Cristina G Negulescu

Stephen A Berry

Michael A Desjardin

Aruna Nathan

Ling-Ling Kang

Pamela J Fereira

Kui Liu

Zhongli Ding

James E Matsuura

Ekaterina S Zlatkova-Karaslavova

Paula Dennis

Latha Narayanan

Stephen Andrew Berry

Latha Pisharody Narayanan

A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.

Suspension formulation comprising an insulinotropic peptide

The present invention relates to osmotic delivery devices, formulations, and methods for delivery of two or more beneficial agents. In one aspect, the present invention provides osmotic delivery devices useful for substantially concurrent administration of two or more beneficial agents. In another aspect, the present invention provides beneficial agent formulations for use in the osmotic delivery devices. The formulations include formulations wherein beneficial agents are soluble in the vehicle, suspension formulations comprising particle formulations of one or more beneficial agent, and combinations thereof. Further, methods for treatment of a variety of diseases or conditions using two or more beneficial agents are disclosed, wherein the methods are preferably practiced using the osmotic delivery devices and/or formulations of the invention.

Devices, formulations, and methods for delivery of multiple beneficial agents

Method of manufacturing an osmotic delivery device

A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.

Methods of manufacturing viscous liquid pharmaceutical formulations

Osmotic delivery device comprising an insulinotropic peptide and uses thereof

A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.

Solvent/polymer solutions as suspension vehicles

Osmotic delivery comprising an insulinotropic peptide and uses thereof

The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Non-aqueous single phase vehicles and formulations utilizing such vehicles

Particle formulations for use in pharmaceutical compositions

Growing community of inventors

Los Altos, CA, United States of America

Catherine Manya Rohloff